% CD19 (B Cells): What Low, High & Normal Percentage Results Mean
Other names: % CD19 (B Cells), CD19 B Cells, CD19 B Cells Low, CD19 B Cells High, CD19 Blood Test, CD19 Absolute Count, Absolute CD19+ Cells, CD19 Lymphocytes, CD19 Cells, CD19+ B Cells, CD19 Percent, CD19 Percentage, CD19 Count, CD19 Normal Range, CD19 Low, CD19 High, Low CD19 B Cells, High CD19 B Cells, CD19 Absolute Count Low, CD19 Absolute Count High, Abs CD19+ Lymphs, CD19+ Lymphs, Total B Cells (CD19+), CD3-CD19+ B Cell, CD19 Pan B Cell, CD19 Pan B Cell Low, CD19 B Cell Count, B Cells CD19, B Lymphocytes CD19, CD19 Lymphs Low, CD19 Pct, CD19%, %CD19, CD19 Level, CD19 Marker, Cluster of Differentiation 19, B-Lymphocyte Antigen CD19, CD19 (B Lymphocyte Marker), CD19 Test, CD19 Lab Test, Lymphocyte B CD19, CD19 Élevé (French), CD19 Bas (French), Lymphocytes B CD19 Bas (French), B-Lymfocyten CD19 Te Hoog (Dutch), B-Lymfocyten CD19 Te Laag (Dutch), CD19 Erhöht (German), CD19 Niedrig (German), B-Lymphozyten CD19 Erhöht (German), Linfocitos B CD19 Bajos (Spanish), Linfocitos CD19 (Spanish), CD19 Valores Normales (Spanish), CD19 Baixo (Portuguese), CD19 B-Лимфоциты Понижены (Russian), CD19 Понижен (Russian), CD19 Limfocyty (Polish), CD19 Oranı (Turkish), تحليل CD19 (Arabic), CD19 منخفض (Arabic)
QUICK ANSWER
The % CD19 (B Cells) test measures what percentage of your lymphocytes are B cells — specifically, CD19-positive B lymphocytes. B cells are a critical part of the immune system: they produce antibodies that fight infections.
Normal range: 6–29% (percentage) or approximately 110–660 cells/μL (absolute count — see Absolute CD19+ Cells). Results below this range indicate low B cells; results above indicate elevated B cells.
The most common reason for a very low or zero CD19 count is B cell depleting medication (rituximab, ocrelizumab, ofatumumab). If you are on one of these drugs, a low result is expected and does not indicate a problem.
Key takeaway: Low CD19 B cells are far more common clinically than high. The most important question when interpreting a low result is: are you on B cell depleting therapy? If yes, a low or zero result is expected. If no, the cause needs investigation.
| Result | % CD19 | Absolute count | Meaning |
|---|---|---|---|
| Low | < 6% | < 110 cells/μL | Immunodeficiency, B cell depletion, bone marrow disorder |
| Normal | 6–29% | 110–660 cells/μL | Healthy B cell population |
| High | > 29% | > 660 cells/μL | B cell lymphoproliferation, autoimmune disease, infection |
WHAT IS THE NORMAL RANGE FOR CD19 B CELLS?
CD19 B cells are reported in two ways on lab reports — often both appear together:
Percentage (% CD19): Measures what fraction of total lymphocytes are CD19+ B cells.
- Normal: 6–29%
- Some labs use 7–24% or 7–23% — always check your specific report's reference range
Absolute count (Absolute CD19+ cells): Measures the actual number of B cells per microliter of blood.
- Normal: approximately 110–660 cells/μL (the reference range on the Absolute CD19+ Cells page; varies by lab)
- Absolute count = total lymphocyte count × CD19%
Which matters more — percentage or absolute count? Both provide useful information but in different contexts:
- Percentage reflects B cells as a proportion of immune cells — useful for assessing immune balance
- Absolute count reflects total B cell burden — more useful for tracking B cell recovery after therapy, or assessing severity of B cell deficiency
- When lymphocyte counts are abnormal (very high or very low), the percentage can be misleading — the absolute count is more reliable in those situations
WHAT DOES LOW CD19 MEAN?
Low CD19 B cells (below 6% or below 100 cells/μL absolute) means your blood contains fewer B lymphocytes than normal. This is clinically significant because B cells produce antibodies — without adequate B cells, the immune system's ability to fight infections is compromised.
The most common causes of low CD19 B cells:
1. B cell depleting therapy (most common cause in clinical practice) Medications specifically designed to deplete B cells will cause very low or zero CD19 results. This is expected and intentional:
- Rituximab (Rituxan) — used in lymphoma, CLL, rheumatoid arthritis, lupus, and other autoimmune diseases
- Ocrelizumab (Ocrevus) — used in multiple sclerosis (MS)
- Ofatumumab (Kesimpta) — used in MS
- Obinutuzumab — used in CLL
- Inebilizumab (Uplizna) — used in neuromyelitis optica
If you are on any of these medications, a low or zero CD19 result is expected and not alarming. CD19 monitoring is used to confirm successful B cell depletion and track recovery between doses.
2. Primary immunodeficiency disorders
- X-linked agammaglobulinemia (XLA/Bruton's disease) — near-total absence of B cells from birth; CD19 is essentially 0
- Common variable immunodeficiency (CVID) — reduced B cell numbers and/or function; most common symptomatic primary antibody deficiency
- Selective IgA deficiency — may be associated with low B cell subsets
3. Secondary (acquired) causes
- HIV/AIDS — progressive immune dysfunction can affect B cell populations
- Post-bone marrow or stem cell transplant — B cells recover slowly after transplant; low CD19 is expected in early post-transplant period
- Chemotherapy — cytotoxic drugs reduce all blood cell populations including B cells
- Immunosuppressive therapy — beyond B cell depleting drugs, broader immunosuppressants can reduce B cell counts
- Chronic infections — prolonged viral infections can deplete B cell populations
4. Haematological malignancies Paradoxically, some B cell cancers result in functionally abnormal B cells that crowd out normal ones, or in bone marrow failure that reduces overall production.
What low CD19 means clinically: Low B cells reduce the body's capacity to produce antibodies (immunoglobulins). Clinically, this manifests as:
- Increased susceptibility to bacterial infections, particularly encapsulated bacteria (pneumococcus, H. influenzae)
- Recurrent sinopulmonary infections
- Low immunoglobulin levels (IgG, IgM, IgA) on blood tests
"CD19 B cells 0" or "absolute count 0": A result of zero or near-zero is almost always due to B cell depleting therapy. Outside of therapy, a true zero B cell count suggests severe primary immunodeficiency (XLA or similar) and requires urgent immunology evaluation.
WHAT DOES HIGH CD19 MEAN?
High CD19 B cells (above 29% or above 500 cells/μL absolute) means elevated numbers of CD19-positive B lymphocytes are present. Mildly elevated results can occur in some infections and autoimmune conditions. Significantly elevated results — particularly with a markedly high absolute count — raise concern for B cell lymphoproliferative disorders.
Causes of high CD19 B cells:
B cell lymphoproliferative disorders (most clinically significant):
- Chronic lymphocytic leukaemia (CLL) — the most common adult leukaemia; characterised by marked accumulation of CD19+ B cells (often >5,000 cells/μL). CLL B cells typically co-express CD5 (a T cell marker), which is unusual and diagnostically important.
- B cell lymphomas — follicular lymphoma, diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma, and others. CD19 is expressed on virtually all B cell lymphomas.
- Acute lymphoblastic leukaemia (ALL) — can present with very high CD19+ blast counts
Infection and immune activation:
- Infectious mononucleosis (EBV) — can transiently elevate B cell counts
- Other viral infections — acute viral infections can cause reactive lymphocytosis with elevated B cell proportion
Autoimmune diseases:
- Systemic lupus erythematosus (SLE) and other autoimmune conditions can be associated with B cell expansion
Important context: A mildly elevated CD19 percentage (e.g. 30–35%) in isolation, with a normal absolute lymphocyte count, is usually not clinically significant and may represent normal biological variation. It is the absolute count and clinical picture that drives concern — not the percentage alone.
CD19 MONITORING DURING B CELL DEPLETING THERAPY
This is one of the most common reasons for CD19 testing in clinical practice and is almost entirely absent from standard consumer health content.
Rituximab (used in lymphoma, CLL, RA, lupus, vasculitis, ITP):
- Rituximab depletes CD19+ (and CD20+) B cells within days of infusion
- CD19 count typically reaches near-zero within 2–4 weeks
- B cell recovery begins at 6–12 months; full recovery can take 2–3 years
- Monitoring CD19 helps assess: (1) successful depletion, (2) B cell recovery before redosing, (3) immunoglobulin supplementation need
Ocrelizumab/Ofatumumab (used in multiple sclerosis):
- These anti-CD20 drugs deplete CD19+ B cells as part of their mechanism
- A low or zero CD19 result is the expected therapeutic effect
- Low CD19 while on ocrelizumab/Kesimpta = treatment working as intended
- Monitoring is used to assess recovery before delayed dosing in patients with infection concerns
What "CD19 = 0 on Ocrevus" means: Many MS patients search specifically for this. A CD19 of 0 while on ocrelizumab is expected — the drug is designed to deplete B cells. It does not mean the immune system has failed or that you are dangerously immunocompromised. Discuss any infection concerns with your neurologist.
% CD19 vs ABSOLUTE CD19: WHAT'S THE DIFFERENCE?
HealthMatters has a dedicated page for the absolute count: Absolute CD19+ Cells. The table below summarises the key differences:
| % CD19 | Absolute CD19 | |
|---|---|---|
| What it measures | B cells as % of total lymphocytes | Actual number of B cells per μL |
| Normal range | 6–29% | ~110–660 cells/μL (this lab) |
| Report label | "% CD19 (B Cells)", "CD19%", "%CD19" | "Absolute CD19+ cells", "CD19 Abs", "Abs CD19+ Lymphs" |
| Best for | Immune balance assessment | B cell depletion/recovery monitoring |
| Limitation | Can be misleading if total lymphocytes are abnormal | Requires accurate total lymphocyte count |
| Dedicated HM page | This page | Absolute CD19+ Cells |
FAQ about % CD19 (B Cells)
-
What does low CD19 mean?
Low CD19 B cells (below 6% or below 110 cells/μL) means fewer B lymphocytes than normal are present in the blood. The most common cause in clinical practice is B cell depleting therapy — rituximab, ocrelizumab, or similar medications. Outside of drug therapy, low CD19 may indicate primary immunodeficiency (CVID, XLA), post-transplant recovery, HIV, or other secondary causes. Low B cells reduce the immune system's ability to produce antibodies. -
What does high CD19 mean?
High CD19 B cells (above 29% or above 500 cells/μL absolute) indicates elevated B lymphocytes. The most clinically significant cause is B cell lymphoproliferative disease — particularly chronic lymphocytic leukaemia (CLL) or B cell lymphoma. Mildly elevated results may occur with viral infections or autoimmune conditions and are often not independently significant. -
What is the normal range for CD19 B cells?
The normal range for % CD19 is approximately 6–29% of lymphocytes. The normal absolute count is approximately 110–660 cells/μL (varies by lab). Reference ranges vary between laboratories — always check the range printed on your specific report. -
What does "absolute CD19+ cells low" mean?
Absolute CD19+ cells low means the actual number of B cells in your blood is below the reference range (typically below 110 cells/μL). This is more clinically informative than the percentage alone, particularly when tracking B cell recovery after therapy or assessing the severity of B cell deficiency. The most common cause is B cell depleting medication. -
Why is my CD19 count 0 or very low while on Ocrevus or rituximab?
A CD19 count of zero or near-zero is the expected and intended result of B cell depleting therapy such as ocrelizumab (Ocrevus), rituximab, or ofatumumab (Kesimpta). These medications work by depleting CD19+ B cells. A result of 0 means the medication is working as intended. This is not an emergency. Discuss any concerns about infection risk or when to expect B cell recovery with your prescribing doctor. -
What causes low CD19 B cells?
The most common cause is B cell depleting medication (rituximab, ocrelizumab, ofatumumab). Other causes include primary immunodeficiency disorders (CVID, X-linked agammaglobulinemia), bone marrow disorders, chemotherapy, post-transplant recovery, HIV, and chronic immunosuppression. The clinical significance depends on the context and severity of the reduction. -
What is CD19 and why is it tested?
CD19 is a protein found on the surface of B lymphocytes — one of the main types of white blood cells involved in immune defence. It is used as a marker to identify and count B cells. The CD19 test is ordered as part of a lymphocyte subset panel to assess immune function, diagnose or monitor lymphoproliferative disorders, and track B cell depletion or recovery in patients on targeted immunotherapy. -
What is the difference between % CD19 and absolute CD19?
% CD19 measures B cells as a proportion of total lymphocytes (normal: 6–29%). Absolute CD19 measures the actual number of B cells per microlitre of blood (normal: ~110–660 cells/μL). Both are often reported together. The absolute count is more useful for tracking B cell depletion and recovery; the percentage is useful for assessing immune balance. When total lymphocyte counts are abnormal, the percentage can be misleading — the absolute count is more reliable. -
What is CD19 deficiency?
CD19 deficiency is a very rare primary immunodeficiency caused by mutations in the CD19 gene. It results in impaired B cell signalling, low immunoglobulin levels, and increased susceptibility to infections — similar to common variable immunodeficiency (CVID) in presentation. It is one of the rarest causes of low CD19 and is distinct from the more common secondary causes. -
Can CD19 B cells recover after being depleted by rituximab or ocrelizumab?
Yes. B cell recovery after rituximab typically begins at 6–9 months and full recovery can take 1–3 years depending on the dose and indication. After ocrelizumab, B cells begin recovering after the last dose and typically reach normal levels within 6–12 months. CD19 monitoring is used to track this recovery. Patients with very prolonged B cell depletion may require immunoglobulin supplementation.
Lab Results Explained and Tracked
What does it mean if your % CD19 (B Cells) result is too high?
High CD19 B cells (above 29% or above 500 cells/μL absolute) indicate an elevated B cell population. The most clinically significant cause is B cell lymphoproliferative disease — particularly chronic lymphocytic leukaemia (CLL), where markedly elevated CD19+ B cells are the defining finding, and B cell lymphomas.
Mildly elevated CD19 in isolation may occur with viral infections or autoimmune conditions and is often not clinically significant.
If your absolute CD19 count is significantly elevated (>1,000 cells/μL) without an obvious infection-related explanation, discuss with your doctor. Further evaluation typically includes a full blood count with differential, peripheral blood immunophenotyping, and haematology review.
Related Health Conditions
All Your Lab Results.
One Simple Dashboard.
Import, Track, and Share Your Lab Results Easily
Import, Track, and Share Your Lab Results
Import lab results from multiple providers, track changes over time, customize your reference ranges, and get clear explanations for each result. Everything is stored securely, exportable in one organized file, and shareable with your doctor—or anyone you choose.
Cancel or upgrade anytime
What does it mean if your % CD19 (B Cells) result is too low?
Low CD19 B cells (below 6% or below 100 cells/μL absolute) indicate a reduced B cell population. The most common cause in clinical practice is B cell depleting therapy — rituximab, ocrelizumab, ofatumumab, and similar medications intentionally reduce CD19 to near zero. In this context, a low result is expected and not alarming.
Outside of B cell depleting therapy, low CD19 may indicate primary immunodeficiency (particularly common variable immunodeficiency or X-linked agammaglobulinemia), post-transplant B cell reconstitution, or secondary immunosuppression.
Low B cell counts reduce antibody production capacity. If CD19 is persistently low without a medication explanation, immunoglobulin levels (IgG, IgM, IgA) should be checked.
Related Biomarkers
Article Review & Sources
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We're committed to accuracy and transparency — see our editorial policy for details.
Laboratories
Bring All Your Lab Results Together — In One Place
We accept reports from any lab, so you can easily collect and organize all your health information in one secure spot.
Pricing Table
Gather Your Lab History — and Finally Make Sense of It
Finally, Your Lab Results Organized and Clear
Personal plans
$79/ year
Advanced Plan
Access your lab reports, explanations, and tracking tools.
- Import lab results from any provider
- Track all results with visual tools
- Customize your reference ranges
- Export your full lab history anytime
- Share results securely with anyone
- Receive 5 reports entered for you
- Cancel or upgrade anytime
$250/ once
Unlimited Account
Pay once, access everything—no monthly fees, no limits.
- Import lab results from any provider
- Track all results with visual tools
- Customize your reference ranges
- Export your full lab history anytime
- Share results securely with anyone
- Receive 10 reports entered for you
- No subscriptions. No extra fees.
$45/ month
Pro Monthly
Designed for professionals managing their clients' lab reports
- Import lab results from any provider
- Track lab results for multiple clients
- Customize reference ranges per client
- Export lab histories and reports
- Begin with first report entered by us
- Cancel or upgrade anytime
About membership
What's included in a Healthmatters membership
Import Lab Results from Any Source
See Your Health Timeline
Understand What Your Results Mean
Visualize Your Results
Data Entry Service for Your Reports
Securely Share With Anyone You Trust
Let Your Lab Results Tell the Full Story
Once your results are in one place, see the bigger picture — track trends over time, compare data side by side, export your full history, and share securely with anyone you trust.
Bring all your results together to compare, track progress, export your history, and share securely.
What Healthmatters Members Are Saying
We implement proven measures to keep your data safe.
At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.